TABLE 2.
Clinical and microbiological characteristics, variables related to fosfomycin therapy, and outcome of episodes of posttransplant AB (n = 137)
| Variablea | Value |
|---|---|
| Age at diagnosis (yrs) (mean ± SD) | 57.7 ± 13.0 |
| Time interval from transplantation to diagnosis of AB (mo) (median [IQR]) | 3.1 (1.1–10.5) |
| AB within the first 2 posttransplant mo (n [%]) | 53 (38.7) |
| Isolated microorganisms (n [%]) | |
| Enterobacterales | 129 (94.2) |
| Escherichia coli | 95 (69.3) |
| Klebsiella pneumoniae | 21 (15.3) |
| Klebsiella oxytoca | 5 (3.6) |
| Proteus mirabilis | 5 (3.6) |
| Citrobacter freundii | 1 (0.7) |
| Enterobacter spp. | 2 (1.5) |
| Nonfermenting Gram-negative bacilli | 3 (2.2) |
| Pseudomonas aeruginosa | 3 (2.2) |
| Gram-positive cocci | 5 (3.6) |
| Staphylococcus epidermidis | 2 (1.5) |
| Enterococcus faecalis | 1 (0.7) |
| Enterococcus faecium | 1 (0.7) |
| Staphylococcus aureus | 1 (0.7) |
| Antibiotic susceptibility testing (n [%]) | |
| Multidrug resistance | 78 (56.9) |
| ESBL production | 28 (20.4) |
| Carbapenem resistance | 4 (2.9) |
| eGFR at diagnosis of AB (ml/min) (mean ± SD)b | 42.8 ± 20.5 |
| eGFR <30 ml/min (n [%]) | 37 (28.2) |
| eGFR <10 ml/min (n [%]) | 3 (2.3) |
| Salvage therapy (n [%]) | 15 (10.9) |
| Daily fosfomycin dose (g) (median [IQR]) | 3 (1.5–3) |
| Duration of fosfomycin therapy (days) (median [IQR]) | 3 (2–9) |
| Fosfomycin formulation (n [%]) | |
| Trometamol fosfomycin | 72 (52.6) |
| Calcium fosfomycin | 65 (47.4) |
| Interval from initiation of therapy to test-of-cure culture (days) (median [IQR]) | 13 (8–21) |
| Interval from end of therapy to test-of-cure culture (days) (median [IQR]) | 9 (3–15.5) |
| Urine culture within the first wk (n [%]) | 31 (22.6) |
| Urine culture within the first mo (n [%]) | 133 (100.0) |
| Microbiological failure at first wk (n [%]) | 13/31 (41.9) |
| Microbiological failure at first mo (n [%]) | 55/137 (40.1) |
a
AB, asymptomatic bacteriuria; eGFR, estimated glomerular filtration rate according to MDRD‐4 variable equation; ESBL, extended‐spectrum β‐lactamase; IQR, interquartile range; SD, standard deviation.
b
eGFR at the time of diagnosis was not available for 6 episodes.